☆ 4.7 Meeting Abstract

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) plus Lenalidomide (Len) Vs Tafa plus Len in Relapsed or Refractory DLBCL

BLOOD (2022)

Get Full Text
Add to Collection

Journal

BLOOD
Volume 140, Issue -, Pages 12066-12067

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2022-158042

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.